Format

Send to

Choose Destination
Nat Rev Cancer. 2002 Oct;2(10):750-63.

Ligand-targeted therapeutics in anticancer therapy.

Author information

1
Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada T6G 2H7. terry.allen@ualberta.ca

Abstract

Cytotoxic chemotherapy or radiotherapy of cancer is limited by serious, sometimes life-threatening, side effects that arise from toxicities to sensitive normal cells because the therapies are not selective for malignant cells. So how can selectivity be improved? One strategy is to couple the therapeutics to antibodies or other ligands that recognize tumour-associated antigens. This increases the exposure of the malignant cells, and reduces the exposure of normal cells, to the ligand-targeted therapeutics.

PMID:
12360278
DOI:
10.1038/nrc903
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center